EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase III)Open Access · CC BY 4.0

Model‐based evaluation of the interaction between ritonavir‐boosted atazanavir and rifampicin in Ugandan adults with HIV

Allan Kengo iD, Juan Eduardo Resendiz-Galvan, Letisha Najjemba iD, Henry Mugerwa, Amedeo De Nicolò, Antonio D'Avolio iD, Shakir Atoyebi iD, Lubbe Wiesner, Elin M Svensson iD, Catriona Waitt iD, Paolo Denti iD

British Journal of Clinical Pharmacology · 2025

DOI: 10.1002/bcp.70195 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Allan Kengo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. Hauptthemen laut MEDLINE: Atazanavir Sulfate, HIV Infections, HIV Protease Inhibitors, Models, Biological. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, European and Developing Countries Clinical Trials Partnership, Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Concomitant treatment of tuberculosis (TB) and human immunodeficiency virus (HIV) is complicated by drug‐drug interactions (DDI). This analysis aimed to characterize the DDI between ritonavir‐boosted atazanavir (ATV/r) and rifampicin in plasma and peripheral blood mononuclear cells (PBMC).

Methods

The DERIVE study (NCT04121195) recruited Ugandan adults with HIV (not TB) on ATV/r‐based second‐line antiretroviral therapy, and collected intensive plasma and PBMC pharmacokinetic samples during four visits: (i) standard‐dose ATV/r 300/100 mg QD, (ii) same ATV/r regimen adding rifampicin 600 mg QD, (iii) doubling ATV/r to BID with rifampicin 600 mg QD and (iv) ATV/r 300/100 mg BID with rifampicin increased to 1200 mg QD. ATV/r plasma and PBMC concentrations were analysed with population pharmacokinetic modelling in NONMEM.

Results

Twenty‐six participants (23 female) were enrolled, with median age and weight of 44 years and 67 kg, respectively. A two‐compartment model with an effect‐compartment effectively described atazanavir concentrations in plasma and PBMC. Rifampicin increased atazanavir clearance threefold, while decreasing its bioavailability and absorption rate. Doubling dosing frequency of ATV/r largely mitigated the interaction with rifampicin, restoring the proportion of simulated participants achieving the targeted trough atazanavir concentration of 0.014 mg/L to 99%. Rifampicin did not affect the ratio of atazanavir concentration between PBMCs and plasma.

Conclusion

Metabolic induction by rifampicin accounts for the decrease in plasma exposure of ATV/r. Doubling the ATV/r dosing frequency to BID effectively mitigated this interaction. The plasma exposure of ATV/r mirrored that in PBMCs, suggesting that for these drugs, plasma concentrations provide a reliable reflection of site‐of‐action exposures.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atazanavir SulfateHIV InfectionsHIV Protease InhibitorsModels, BiologicalRifampinRitonavirAdultFemaleHumansMaleMiddle AgedYoung AdultDrug InteractionsDrug Therapy, CombinationLeukocytes, MononuclearTuberculosisUganda

Stichwörter der Autor:innen

antiretroviralsdrug interactionspharmacokineticspharmacometrics

Substanzen

Atazanavir SulfateHIV Protease InhibitorsRifampinRitonavir

Autor:innen und Institutionen

  • Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
  • Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
  • Joint Clinical Research Centre, Research Department, Kampala, Uganda.
  • Department of Medical Sciences, University of Turin, Turin, Italy.
  • Department of Women's and Children's Health, University of Liverpool, Liverpool, United Kingdom.
  • Department of Pharmacy, Uppsala University, Uppsala, Sweden.

ORCID-Profile: Allan Kengo, Letisha Najjemba, Antonio D'Avolio, Shakir Atoyebi, Elin M Svensson, Catriona Waitt, Paolo Denti

Förderung

  • NIAID NIH HHS
  • European and Developing Countries Clinical Trials Partnership
  • Wellcome Trust
  • Wellcome Clinical Research Career Development
  • University of Cape Town
  • Universityof CapeTown

Zitieren

APA

Kengo, A., Resendiz-Galvan, J. E., Najjemba, L., Mugerwa, H., De Nicolò, A., D'Avolio, A., Atoyebi, S., Wiesner, L., Svensson, E. M., Waitt, C., & Denti, P. (2025). Model‐based evaluation of the interaction between ritonavir‐boosted atazanavir and rifampicin in Ugandan adults with HIV. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70195

Vancouver

Kengo A, Resendiz-Galvan JE, Najjemba L, Mugerwa H, De Nicolò A, D'Avolio A, et al. Model‐based evaluation of the interaction between ritonavir‐boosted atazanavir and rifampicin in Ugandan adults with HIV. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70195

BibTeX
@article{Kengo2025,
  author = {Kengo, Allan and Resendiz-Galvan, Juan Eduardo and Najjemba, Letisha and Mugerwa, Henry and De Nicolò, Amedeo and D'Avolio, Antonio and Atoyebi, Shakir and Wiesner, Lubbe and Svensson, Elin M and Waitt, Catriona and Denti, Paolo},
  title = {Model‐based evaluation of the interaction between ritonavir‐boosted atazanavir and rifampicin in Ugandan adults with HIV},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/bcp.70195}
}
Kostenlos starten →